315 related articles for article (PubMed ID: 30417781)
1. Small Molecules as PD-1/PD-L1 Pathway Modulators for Cancer Immunotherapy.
Jiao P; Geng Q; Jin P; Su G; Teng H; Dong J; Yan B
Curr Pharm Des; 2018; 24(41):4911-4920. PubMed ID: 30417781
[TBL] [Abstract][Full Text] [Related]
2. PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules.
Geng Q; Jiao P; Jin P; Su G; Dong J; Yan B
Curr Pharm Des; 2018 Feb; 23(39):6033-6041. PubMed ID: 28982322
[TBL] [Abstract][Full Text] [Related]
3. Insights into non-peptide small-molecule inhibitors of the PD-1/PD-L1 interaction: Development and perspective.
Wu X; Meng Y; Liu L; Gong G; Zhang H; Hou Y; Liu C; Wu D; Qin M
Bioorg Med Chem; 2021 Mar; 33():116038. PubMed ID: 33517226
[TBL] [Abstract][Full Text] [Related]
4. Advances of biphenyl small-molecule inhibitors targeting PD-1/PD-L1 interaction in cancer immunotherapy.
Chen R; Yuan D; Ma J
Future Med Chem; 2022 Jan; 14(2):97-113. PubMed ID: 34870447
[TBL] [Abstract][Full Text] [Related]
5. Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1.
Guzik K; Zak KM; Grudnik P; Magiera K; Musielak B; Törner R; Skalniak L; Dömling A; Dubin G; Holak TA
J Med Chem; 2017 Jul; 60(13):5857-5867. PubMed ID: 28613862
[TBL] [Abstract][Full Text] [Related]
6. Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?
Chen T; Li Q; Liu Z; Chen Y; Feng F; Sun H
Eur J Med Chem; 2019 Jan; 161():378-398. PubMed ID: 30384043
[TBL] [Abstract][Full Text] [Related]
7. Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation.
Pan C; Yang H; Lu Y; Hu S; Wu Y; He Q; Dong X
Eur J Med Chem; 2021 Mar; 213():113170. PubMed ID: 33454550
[TBL] [Abstract][Full Text] [Related]
8. Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules.
Lin X; Lu X; Luo G; Xiang H
Eur J Med Chem; 2020 Jan; 186():111876. PubMed ID: 31761384
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules.
Yang J; Hu L
Med Res Rev; 2019 Jan; 39(1):265-301. PubMed ID: 30215856
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).
Zak KM; Grudnik P; Guzik K; Zieba BJ; Musielak B; Dömling A; Dubin G; Holak TA
Oncotarget; 2016 May; 7(21):30323-35. PubMed ID: 27083005
[TBL] [Abstract][Full Text] [Related]
11. Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions.
Chen S; Song Z; Zhang A
Curr Top Med Chem; 2019; 19(3):180-185. PubMed ID: 30854972
[TBL] [Abstract][Full Text] [Related]
12. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X; Huang Z; Teng F; Xing L; Yu J
Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
[TBL] [Abstract][Full Text] [Related]
13. Small Molecule Inhibitors of Programmed Cell Death Ligand 1 (PD-L1): A Patent Review (2019-2021).
Deng J; Cheng Z; Long J; Dömling A; Tortorella M; Wang Y
Expert Opin Ther Pat; 2022 May; 32(5):575-589. PubMed ID: 35272536
[TBL] [Abstract][Full Text] [Related]
14. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Blockade in Breast Cancer Therapy.
Bu X; Yao Y; Li X
Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
[TBL] [Abstract][Full Text] [Related]
16. Discovery of quinazoline derivatives as novel small-molecule inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction.
Wang Y; Kun Huang ; Gao Y; Yuan D; Ling L; Liu J; Wu S; Chen R; Li H; Xiong Y; Liu H; Ma J
Eur J Med Chem; 2022 Feb; 229():113998. PubMed ID: 34839997
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy.
Zhang H; Xia Y; Yu C; Du H; Liu J; Li H; Huang S; Zhu Q; Xu Y; Zou Y
Molecules; 2021 Jun; 26(11):. PubMed ID: 34199417
[TBL] [Abstract][Full Text] [Related]
18. Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways.
Sasikumar PG; Ramachandra M
BioDrugs; 2018 Oct; 32(5):481-497. PubMed ID: 30168070
[TBL] [Abstract][Full Text] [Related]
19. The Characteristics of PD-L1 Inhibitors, from Peptides to Small Molecules.
Zhong Y; Li X; Yao H; Lin K
Molecules; 2019 May; 24(10):. PubMed ID: 31137573
[TBL] [Abstract][Full Text] [Related]
20. Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint.
Konieczny M; Musielak B; Kocik J; Skalniak L; Sala D; Czub M; Magiera-Mularz K; Rodriguez I; Myrcha M; Stec M; Siedlar M; Holak TA; Plewka J
J Med Chem; 2020 Oct; 63(19):11271-11285. PubMed ID: 32936638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
